-
公开(公告)号：US07666900B2
公开(公告)日：2010-02-23
申请号：US10586338
申请日：2004-12-22
申请人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
CPC分类号： A61K31/385 , A61K31/05 , A61K31/122 , Y10S514/824
摘要： To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
摘要翻译： 提供用于低HDL胆固醇血症的药学上有效的预防/预防药物，重点是HDL生成机制。 本发明的ABCA1稳定剂含有选自普罗布考螺醌，普罗布考二苯醌和普罗布考双酚作为有效成分的双酚型化合物。 ABCA1稳定剂可以通过与常规方法完全不同的机制连续稳定地表达ABCA1，因此可用作低HDL胆固醇血症或动脉硬化的预防/预防剂。
-
公开(公告)号：US20070010456A1
公开(公告)日：2007-01-11
申请号：US11520626
申请日：2006-09-14
申请人： Shinji Yokoyama , Reijiro Arakawa
发明人： Shinji Yokoyama , Reijiro Arakawa
摘要： The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
-
公开(公告)号：US20060128003A1
公开(公告)日：2006-06-15
申请号：US11337446
申请日：2006-01-24
申请人： Shinji Yokoyama , Reijiro Arakawa
发明人： Shinji Yokoyama , Reijiro Arakawa
摘要： The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
摘要翻译： 本发明提供低HDL-胆固醇血症药物，预防和/或治疗性抗动脉硬化药物以及预防和治疗低HDL-胆固醇血症，动脉硬化及其相关疾病或病症的方法，其重点在于改善 HDL，而不诉诸基因工程技术。 此外，本发明提供一种低HDL-胆固醇血症的临床有效药剂和包含至少一种半胱氨酸蛋白酶抑制剂作为活性成分的预防和/或治疗性抗动脉硬化剂，从而增加表达的ABCA1的量和提高血液HDL 水平，不使用遗传工程技术。
-
公开(公告)号：US20070269527A1
公开(公告)日：2007-11-22
申请号：US11819674
申请日：2007-06-28
申请人： Shinji Yokoyama , Reijiro Arakawa
发明人： Shinji Yokoyama , Reijiro Arakawa
IPC分类号： A61K35/12
摘要： The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
摘要翻译： 本发明提供低HDL-胆固醇血症药物，预防和/或治疗性抗动脉硬化药物以及预防和治疗低HDL-胆固醇血症，动脉硬化及其相关疾病或病症的方法，其重点在于改善 HDL，而不诉诸基因工程技术。 此外，本发明提供一种低HDL-胆固醇血症的临床有效药剂和包含至少一种半胱氨酸蛋白酶抑制剂作为活性成分的预防和/或治疗性抗动脉硬化剂，从而增加表达的ABCA1的量和提高血液HDL 水平，不使用遗传工程技术。
-
公开(公告)号：US20070161702A1
公开(公告)日：2007-07-12
申请号：US10586338
申请日：2004-12-22
申请人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Maki Tsujita , Reijiro Arakawa , Tomoji Aotsuka
IPC分类号： A61K31/343 , A61K31/05
CPC分类号： A61K31/385 , A61K31/05 , A61K31/122 , Y10S514/824
摘要： To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
摘要翻译： 提供用于低HDL胆固醇血症的药学上有效的预防/预防药物，重点是HDL生成机制。 本发明的ABCA1稳定剂含有选自普罗布考螺醌，普罗布考二苯醌和普罗布考双酚作为有效成分的双酚型化合物。 ABCA1稳定剂可以通过与常规方法完全不同的机制连续稳定地表达ABCA1，因此可用作低HDL胆固醇血症或动脉硬化的预防/预防药物。
-
公开(公告)号：US20050085408A1
公开(公告)日：2005-04-21
申请号：US10492482
申请日：2002-10-11
申请人： Shinji Yokoyama , Reijiro Arakawa
发明人： Shinji Yokoyama , Reijiro Arakawa
IPC分类号： A61K31/00 , A61K38/00 , A61K38/05 , A61K38/55 , A61K38/56 , A61K38/57 , A61P3/06 , A61P9/10 , A61P43/00 , A61K38/04
摘要： The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
摘要翻译： 本发明提供低HDL-胆固醇血症药物，预防和/或治疗性抗动脉硬化药物以及预防和治疗低HDL-胆固醇血症，动脉硬化及其相关疾病或病症的方法，其重点在于改善 HDL，而不诉诸基因工程技术。 此外，本发明提供一种低HDL-胆固醇血症的临床有效药剂和包含至少一种半胱氨酸蛋白酶抑制剂作为活性成分的预防和/或治疗性抗动脉硬化剂，从而增加表达的ABCA1的量和提高血液HDL 水平，不使用遗传工程技术。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
